mRNA-LPA vaccine targeting EWSR1-FLI1

The **mRNA-LPA vaccine targeting EWSR1-FLI1** is an investigational mRNA-based therapeutic vaccine designed to elicit an immune response against the EWSR1-FLI1 fusion oncoprotein, the hallmark driver of Ewing sarcoma (EwS), a rare pediatric bone and soft tissue cancer. It employs lipid nanoparticle (LPA)-encapsulated mRNA encoding neoantigens derived from the EWSR1::FLI1 fusion breakpoint to stimulate T-cell mediated cytotoxicity against tumor cells expressing this fusion protein. This approach exploits the tumor-specific neoantigen presented by the chimeric transcription factor, potentially offering a targeted immunotherapy with minimal off-target effects, though no specific developer or clinical data is confirmed in available sources.